Keyphrases
Acute Lymphoblastic Leukemia
20%
Age Groups
25%
Aging Characteristics
25%
Azacitidine
50%
CD22
10%
Central Nervous System Tumors
50%
Complete Remission
10%
Confidence Interval
20%
Diffuse Glioma
25%
Gemtuzumab Ozogamicin
50%
Glioma Subtypes
50%
Group Studies
50%
High Risk
25%
Incidence Characteristics
25%
Infant Acute Lymphoblastic Leukemia
10%
Infant Patients
50%
Juvenile Myelomonocytic Leukemia
50%
Malignant Tumor
41%
Minimal Residual Disease
20%
Myelodysplastic Syndrome
50%
Netherlands
50%
Neutralizing Effect
25%
Non-malignant Tumor
16%
Observed Survival
16%
Overall Survival
15%
Pediatric Glioma
50%
Pediatric Patients
50%
Pharmacokinetics
10%
Phase II Study
50%
Pilocytic Astrocytoma
33%
Population-based Cohort Study
50%
Population-based Study
100%
Preadolescent children
50%
Relapsed Disease
10%
Relapsed or Refractory Acute Myeloid Leukemia
50%
Second Allogeneic Stem Cell Transplantation
10%
Sex Differences
25%
Sex-related
50%
Survival Characteristics
25%
Survival Disparities
50%
Survival Gap
25%
Survival Outcomes
33%
Survival Rate
50%
Treatment Characteristics
25%
Tumor Characteristics
25%
Venous Disease
10%
Vidaza
50%
Working Diagnosis
10%
Young Adolescents
50%
Young children
50%
Medicine and Dentistry
Acute Lymphoblastic Leukemia
50%
Adolescence
50%
Adverse Event
5%
Allograft
10%
Azacitidine
50%
Bone Marrow Toxicity
5%
Cancer Registry
8%
Central Nervous System Tumor
50%
Clinical Trial
5%
Deterioration
8%
Diagnosis
8%
Disease
15%
Hematologic Malignancy
5%
Hematopoietic Stem Cell Transplantation
20%
Inotuzumab Ozogamicin
50%
Juvenile Myelomonocytic Leukemia
50%
Malignant Neoplasm
41%
Minimal Residual Disease
20%
Mortality Rate
8%
Myelodysplastic Syndrome
50%
Neoplasm
16%
Optic Nerve Tumor
8%
Overall Survival
15%
Pediatrics
8%
Pediatrics Patient
50%
Pharmacokinetics
10%
Pilocytic Astrocytoma
33%
Recommended Drug Dose
5%
Survival Rate
50%
Toddlers
50%
Transplantation
10%
Tumor of Central Nervous System
8%
Vein Occlusion
10%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Lymphoblastic Leukemia
50%
Adverse Event
5%
Azacitidine
50%
Bone Marrow Toxicity
5%
Cancer Registry
7%
Central Nervous System Tumor
50%
Clinical Trial
5%
Deterioration
7%
Disease
15%
Hematologic Malignancy
5%
Inotuzumab Ozogamicin
50%
Juvenile Myelomonocytic Leukemia
50%
Malignant Neoplasm
35%
Minimal Residual Disease
20%
Mortality Rate
7%
Myelodysplastic Syndrome
50%
Neoplasm
14%
Optic Nerve Tumor
7%
Overall Survival
15%
Pharmacokinetics
10%
Pilocytic Astrocytoma
28%
Remission
10%
Survival Rate
50%
Vein Occlusion
10%
